Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1985 · 2.6K citations

Medicine, Immunology, Oncology +15

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Elizabeth A. Grimm, R J Robb, Jack A. Roth et al. · The Journal of Experimental Medicine · 1983 · 354 citations · Full text

Life Sciences, Cell Biology, Immunology +12

Lymphokine-activated killer cell activity

Ronald B. Herberman, John C. Hiserodt, Nicola L. Vujanovic et al. · Immunology Today · 1987 · 236 citations

Life Sciences, Cell Biology, Immunology +11

Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer

Constantin N. Baxevanis, George J. Reclos, Angelos D. Gritzapis et al. · Cancer · 1993 · 113 citations · Full text

Life Sciences, Immunology, Oncology +15